• Sulfo-NHS-SS-Biotin: Protocols for Cleavable Protein Labelin

  2026-06-09

  Sulfo-NHS-SS-Biotin offers a water-soluble, amine-reactive biotinylation solution for selective labeling of primary amines, particularly on cell surface proteins, without membrane penetration. It enables reversible biotin tagging, facilitating affinity purification and analysis workflows. It is unsuitable for intracellular labeling or workflows incompatible with its rapid hydrolysis and disulfide-cleavable design.

• Neurotensin: Precision Neurotensin Receptor 1 Activator for

  2026-06-08

  Neurotensin (CAS 39379-15-2) empowers robust, reproducible GPCR trafficking and miRNA regulation assays by directly activating neurotensin receptor 1. This guide details protocol enhancements, troubleshooting, and innovative workflow integration, leveraging APExBIO’s high-purity formulation.

• Coronavirus Macrodomains Counteract PARP-Mediated Antiviral

  2026-06-08

  This study demonstrates that the coronavirus macrodomain is essential for evading host poly (ADP-ribose) polymerase (PARP)-mediated inhibition of viral replication and for modulating interferon responses. These findings clarify the mechanistic interplay between viral macrodomains and host innate immunity, suggesting new antiviral targets and providing a framework for future research on ADP-ribosylation dynamics.

• Iron-Dependent KDM4D and PI3K-Akt-Foxo1 Regulation in MSC Qu

  2026-06-07

  This study uncovers how iron-dependent KDM4D activity controls the balance between quiescence and activation in mesenchymal stem cells (MSCs) via the PI3K-Akt-Foxo1 signaling pathway. These findings clarify epigenetic mechanisms linking iron deficiency to impaired bone remodeling, providing mechanistic insight and intervention points for metabolic bone disorders.

• Biomimetic mRNA Nanovaccines Target Neutrophils in Liver Can

  2026-06-06

  A recent study introduces a biomimetic mRNA nanovaccine platform (CMNPs) that selectively targets tumor-associated neutrophils in hepatocellular carcinoma using engineered CD300LD-coated liposomes and IL-36γ mRNA. This approach significantly enhances anti-tumor immunity, improving survival rates and highlighting new opportunities for neutrophil-driven immunotherapies.

• Resazurin Sodium Salt: Advancing Cell Viability in Translati

  2026-06-05

  Explore how resazurin sodium salt, a fluorogenic oxidation-reduction indicator, empowers translational researchers with quantitative, mechanism-driven cell viability insights. Bridging mechanistic understanding with practical guidance, this article contextualizes the dye's role in metabolic disease and cancer research, highlights protocol nuances, and envisions its impact in deciphering microbiota–host interactions.

• Nonivamide: Applied Protocols and Innovations in TRPV1 Cance

  2026-06-05

  Nonivamide, a capsaicin analog, is transforming TRPV1-focused cancer and neuroimmune research through precise apoptosis induction and anti-inflammatory modulation. This article translates recent reference breakthroughs and robust protocol enhancements into actionable guidance for researchers seeking reliable, reproducible outcomes.

• TBK1 Inhibition Reduces Microglial Pyroptosis in Diabetic Ne

  2026-06-04

  Liao et al. (2024) identify TANK-binding kinase 1 (TBK1) as a central mediator of painful diabetic neuropathy (PDN) through its role in microglial pyroptosis. This study demonstrates that both genetic and pharmacological inhibition of TBK1 attenuate neuropathic pain and neuroinflammation in diabetic mouse models, revealing a promising therapeutic avenue for PDN.

• AMPK as a Dual Regulator of Autophagy: Revisiting ULK1-Vps34

  2026-06-04

  A recent study redefines the role of AMPK in autophagy, demonstrating that it inhibits rather than activates ULK1 and autophagy initiation during energy stress. These findings reshape our understanding of autophagy regulation and have direct implications for research using Vps34 inhibitors to dissect pathway specificity and energy-sensing responses.

• AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosid

  2026-06-03

  This article delivers a scenario-driven, evidence-based guide on using AICAR (5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside) (SKU A8184) to address reproducibility, sensitivity, and workflow challenges in cell viability and inflammation assays. Drawing on validated protocols and the latest literature, it demonstrates how AICAR enables reliable modulation of energy metabolism and inflammatory pathways for advanced metabolic disease research.

• Applied Workflows with the HyperScribe SP6 High Yield RNA Sy

  2026-06-03

  The HyperScribe SP6 High Yield RNA Synthesis Kit empowers high-yield, flexible RNA synthesis for cutting-edge applications from RNA vaccines to advanced probe generation. Discover workflow enhancements, troubleshooting insights, and how this SP6 RNA polymerase kit bridges translational gaps in antiviral research.

• WP1066, JAK2/STAT3 Inhibitor: Applied Protocols & Innovation

  2026-06-02

  WP1066, a cell-permeable JAK2/STAT3 inhibitor, enables precision targeting of oncogenic and regenerative signaling pathways. This article details optimized workflows, key innovations, and troubleshooting strategies to maximize assay success in cancer and bone regeneration models.

• TRIM21-ERK1/2 Axis Drives Proliferation and Resistance in Pi

  2026-06-02

  The referenced study uncovers TRIM21 as a central promoter of cell proliferation and drug resistance in pituitary adenomas by regulating ERK1/2 ubiquitination and phosphorylation. This work highlights the therapeutic potential of targeting TRIM21, including with epigenetic modulators such as Quisinostat, to overcome resistance in dopamine-resistant pituitary tumors.

• N1-Methylpseudouridine: Optimizing Modified Nucleoside mRNA

  2026-06-01

  N1-Methylpseudouridine transforms mRNA experimental design by maximizing translation efficiency and minimizing immune activation. This guide delivers actionable protocols, troubleshooting, and comparative insights for researchers advancing CRISPR-based transcriptomics and therapeutic protein expression.

• CDK4 Modulates 4E-BP1 to Drive Cap-Dependent Translation in

  2026-06-01

  This study uncovers cyclin-dependent kinase 4 (CDK4) as a direct regulator of the translational repressor 4E-BP1, promoting cap-dependent translation during the mitosis–G1 transition. The findings redefine the landscape of translation control in the cell cycle and highlight new avenues for targeting aberrant protein synthesis in disease contexts.

447 records 15/30 page Previous Next First page 上5页 1112131415 下5页 Last page